Wells Fargo lowered its price target on September 5, 2025, following trial results related to Wave Life Sciences.
1 report, 1 independent
Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Wells Fargo lowered its price target on September 5, 2025, following trial results related to Wave Life Sciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Wells Fargo
American multinational banking and financial services company
-
Wave Life Sciences
biotechnology company
Related events
- Analyst cut price target due to pricing pressure for Carnival Corporation, involving Wells Fargo.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Wells Fargo raised its price objective for Urban Outfitters stock, and Jefferies Financial Group lifted its price target for the company on August 1, 2026.
- Major financial firms, including Raymond James, Wells Fargo, Bank of America, and Morgan Stanley, have recently adjusted price targets and issued rating updates.
- CNBC featured Target on its Halftime Report, while Wells Fargo influenced Target's stock price outlook.
Coverage
Newest first; wire copies grouped- TipRanksB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’ B. Riley reiterates a Buy rating on Wave Life Sciences (WVE) with a $19 price target after the company announced RestorAATion-2 data.